Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma
Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma
复制标题
DOI：
10.1093/neuonc/nov028
复制
发表时间：
2015-08-01
期刊：
影响因子：
15.9
通讯作者：
Radbruch, Alexander
中科院分区：
文献类型：
--
作者：
Kickingereder, Philipp;Wiestler, Benedikt;Radbruch, Alexander
背景。分析动态敏感性加权对比增强MRI （DSC-MRI）衍生的相对脑血容量（rCBV）分析在预测复发性胶质母细胞瘤（rGB）患者对贝伐单抗（BEV）的反应中的相关性。共有127例诊断为rGB的患者接受贝伐单抗（71例，BEV队列）或烷基化化疗（56例，非BEV队列），在基线和治疗开始后的首次随访时接受常规解剖MRI和DSC-MRI检查。使用Cox比例风险模型、logistic回归和log-rank检验，对比增强肿瘤（cT1）的平均rCBV以及cT1和液体衰减反转恢复（FLAIR）体积在两个时间点与无进展生存（PFS）和总生存（OS）相关。基线rCBV与两种PFS相关(风险比[HR] = 1.3
Background. To analyze the relevance of dynamic susceptibility-weighted contrast-enhanced MRI (DSC-MRI) derived relative cerebral blood volume (rCBV) analysis for predicting response to bevacizumab (BEV) in patients with recurrent glioblastoma (rGB).Methods. A total of 127 patients diagnosed with rGB receiving either bevacizumab (71 patients, BEV cohort) or alkylating chemotherapy (56 patients, non-BEV cohort) underwent conventional anatomic MRI and DSC-MRI at baseline and at first follow-up after treatment initiation. The mean rCBV of the contrast-enhancing tumor (cT1) as well as cT1 and fluid-attenuated inversion recovery (FLAIR) volumes at both time points were correlated with progression-free survival (PFS) and overall survival (OS) using Cox proportional hazard models, logisticregression, and the log-rank test.Results. Baseline rCBV was associated with both PFS (hazard ratio [HR] = 1.3; P